H.C. Wainwright lowered the firm’s price target on Genmab (GMAB) to $35 from $37 and keeps a Buy rating on the shares following the Q1 report. The firm continues to believe that the company is “well situated to weather further attrition” in the biotech sector because of its track record of profitability, strong balance sheet, solid positioning in the multiple myeloma arena, and broad pipeline with potential for numerous near- and medium-term clinical data catalysts.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Executes Share Buy-back Transactions in May 2025
- Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
- Genmab’s Strong Performance Overshadowed by Patent Expiration Concerns and Competitive Challenges
- Genmab upgraded to Buy from Hold at Nordea
- Genmab Reports Strong Q1 2025 Earnings Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue